AQUILAB Ushers In MVision’s Innovative and Guideline-Compliant AI Segmentation Solution to France

Helsinki – 29th of September 2021 – MVision AI, the leading service provider of guideline compliant radiotherapy software, announces a new distribution partnership with AQUILAB, the chief provider of revolutionary oncology software solutions throughout France. 

The agreement entitled AQUILAB the rights to distribute products and services of MVision AI in France. AQUILAB and MVision AI will support the commitment to help oncology departments to receive the highest quality, guideline-based, deep learning radiotherapy solution throughout France. MVision AI’s team will be working closely with AQUILAB to ensure the distribution of swift, steady, and secure radiotherapy services. 

The agreement entitled AQUILAB with the rights to distribute products and services of MVision AI in France. MVision AI and AQUILAB are committed to helping oncology clinics to provide the most innovative, guideline-compliant, AI segmentation radiotherapy solutions for patients. 

“For more than 20 years, AQUILAB ( has developed advanced software solutions to improve quality in cancer treatment. In Radiotherapy, we offer contouring solutions, participate in RT QA in clinical trials and we are fully involved in many training workshops. In all these activities, we see that harmonization and standardization of the contouring process is one of the main issues to reduce variability and improve quality in radiotherapy treatments. In this context, we are very happy to have a partnership with MVision, to propose automatic AI contouring solutions in French language countries. We think that this solution, based on international guidelines, will permit our users to fully improve the performance and the quality of their contouring workflow,” said David Gibon, President and CEO of AQUILAB. 

As stated by Mahmudul Hasan, CEO, and co-founder of MVision AI, “MVision AI is delighted to partner with AQUILAB to bring guideline-compliant AI segmentation for French patients. France is pioneering deep learning development in its implementation and advocacy of AI initiatives. We are glad to see France’s enthusiasm and curiosity towards artificial intelligence. We are grateful for this support. We have been looking forward to introducing swift, reliable, and high-quality AI segmentation solutions for cancer patients undergoing radiotherapy.” 

Learn more about incorporating AQUILAB’s solutions into your clinic here:

250 rue Salvador Allende – 59120 Loos – France

 Tel:  +33 3 69 61 51 51




Discover guideline-compliant AI segmentation with MVision here:

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland

Tel: +358 (0) 40 5489 229


Email: info@ 


For media inquiries:

Tel: +358 40 500 7915


Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts


World Cancer Day – Joining efforts for a better cancer care

World cancer day, celebrated on the 4th of February, was established more than 20 years ago. It represents an initiative of the Union for International Cancer Control (UICC) , the oldest and largest global membership organization dedicated to taking action on cancer. UICC has over 1150 member organizations in 172…



How can AI-based auto-contouring improve the life of patients who need palliative radiation therapy?

Cancer is one of the leading causes of morbidity and death, worldwide. Approximately 18 million people are diagnosed with cancer each year and the number is expected to increase. Pain is experienced by two thirds of patients having advanced, metastatic or terminal disease (1). Other symptoms caused by compression on…



MVision AI Announces Partnership with Medron Medical Systems (Canada)

HELSINKI, Finland - January 22, 2024 MVision AI, a premier software service provider of GBS™ (Guideline-Based Segmentation) solution for same-day radiotherapy treatment planning, proudly announces a new distribution partnership with Medron Medical Systems, a leading health equipment provider in Canada. This collaboration follows the receipt of Medical Device License (MDL)…

Press Releases